Target, Home Depot,...
Health Care: Drugs
Neuralstem Inc. (CUR: AMEX)
$1.49 0.04 | 2.76%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 407.71K | 390.62K | 733.44K | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 407.71K | 390.62K | 733.44K | 0.00 |
| Selling, General, and Administrative Expenses | 4.25M | 5.84M | 6.62M | 5.03M |
| Research & Development | 6.11M | 7.35M | 9.16M | 5.35M |
| Operating Income before D & A (EBITDA) | -9.95M | -12.80M | -15.05M | -10.38M |
| Depreciation & Amortization | 211.14K | 187.05K | 130.75K | 88.66K |
| Interest Income | 34.15K | 60.96K | 59.28K | 19.61K |
| Other Income - Net | 3.48K | 411.81K | -3.26M | 83.35K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -10.12M | -12.52M | -18.38M | -10.36M |
| Interest Expense | 2.70K | 821.00 | 2.66K | 776.00 |
| Pre-Tax Income | -10.12M | -12.52M | -18.39M | -10.36M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -10.12M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -10.12M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -10.12M | -12.52M | -18.39M | -10.36M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-10.12M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -10.12M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.17 | -0.26 | -0.42 | -0.30 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.17 | -0.26 | -0.42 | -0.30 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.17 | -0.26 | -0.42 | -0.30 |
| Basic Normalized Net Income/Share | -0.17 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.17 | -0.26 | -0.42 | -0.30 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.17 | -0.26 | -0.42 | -0.30 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.17 | -0.26 | -0.42 | -0.30 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.17 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CUR
- Portfolio NameUser Type
- Userdennis diamonds
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Usermine
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserBio
- Userjustin
- ContributorBreakout Stocks Of The Week...
Latest CUR Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 05.09.13 | 01:05 pm
- 4 Biotech Stocks Under $10 Moving Higher 11.27.12 | 02:11 pm
- 4 Biotech Stocks Under $10 Moving Higher 10.05.12 | 08:10 am
- Stocks Close Week Higher on QE3 Confidence 09.14.12 | 05:09 pm
- 5 Stocks Under $10 Setting Up to Break Out 09.13.12 | 12:09 pm
- 5 Stocks Poised for Big Breakouts 08.31.12 | 01:08 pm
- 9 Biotech Penny Stocks to Buy 08.31.10 | 10:08 am
- Interstate Hotel, Neuralstem: Midday Volume Plays 12.18.09 | 01:12 pm
- Four Must-See Charts: Stem Cell Stocks 07.02.09 | 03:07 pm
- Stem cell firms jump on Obama policy plans 03.06.09 | 06:03 pm
Press Releases for CUR
- Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London - PR Newswire 05.16.13 | 09:05 am
- DiagnoCure Announces Presentation On Previstage GCC At The 2013 ASCO Annual Meeting - PR Newswire 05.16.13 | 07:05 am
- Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress - PR Newswire 05.13.13 | 09:05 am
- Neuralstem ALS Trial Investigator And Patient On Sirius XM - PR Newswire 05.08.13 | 09:05 am
- Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting - PR Newswire 04.29.13 | 11:04 am
- DiagnoCure's Update Presentation During The Annual And Special Meeting Of Shareholders - PR Newswire 04.29.13 | 07:04 am
- Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment - PR Newswire 04.24.13 | 09:04 am
- FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder - PR Newswire 04.22.13 | 09:04 am
- Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention - PR Newswire 04.18.13 | 09:04 am
- Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis - PR Newswire 04.17.13 | 08:04 am
Partner Headlines for CUR
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned - Seeking Alpha 12.16.12 | 08:12 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- 4 Biotechs That Just Got Mauled By Bears - Seeking Alpha 10.10.12 | 09:10 am
- Morning Market Movers - Benzinga 10.04.12 | 09:10 am
- Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem ALS Trial - Benzinga 10.04.12 | 09:10 am
- Neuralstem Grants First Licenses for CNS Therapy Surgical Devices - Benzinga 09.06.12 | 09:09 am
- ALS Patient's Survival is "One of the Most Powerful Stories" Ever Reported - Benzinga 08.27.12 | 01:08 pm
- End-of-Day Market Summary for November 23, 2011 - Benzinga 11.23.11 | 04:11 pm
